Answers are grounded in this paper and cite their sources.
Class IV evidence shows sustained migraine headache days reduction with anti-CGRP monoclonal antibodies, indicating treatment effectiveness.
This study provides Class IV evidence that, in patients with migraine, treatment with anti-CGRP MAbs is associated with sustained reductions in MHDs over a 24-month period.
No takes yet. Share an insight, caveat, or question.
Caronna et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: